|
|
|
|
| LEADER |
02450nam a22002775i 4500 |
| 001 |
000278689 |
| 005 |
20211026202613.0 |
| 007 |
cr nn 008mamaa |
| 008 |
100301s2005 xxu| s |||| 0|eng d |
| 020 |
|
|
|a 9781592598847
|
| 024 |
7 |
|
|a 10.1007/978-1-59259-884-7
|2 doi
|
| 040 |
|
|
|a Sistema de Bibliotecas del Tecnológico de Costa Rica
|
| 245 |
1 |
0 |
|a Cardiac Safety of Noncardiac Drugs :
|b Practical Guidelines for Clinical Research and Drug Development /
|c edited by Joel Morganroth, Ihor Gussak.
|
| 250 |
|
|
|a 1st ed. 2005.
|
| 260 |
# |
# |
|a Totowa, NJ :
|b Humana Press :
|b Imprint: Humana,
|c 2005.
|
| 300 |
|
|
|a XII, 362 p. :
|b online resource.
|
| 336 |
|
|
|a text
|b txt
|2 rdacontent
|
| 337 |
|
|
|a computer
|b c
|2 rdamedia
|
| 338 |
|
|
|a online resource
|b cr
|2 rdacarrier
|
| 505 |
0 |
|
|a Cardiac Safety of Noncardiac Drugs -- Preclinical and Pharmacogenomic Cardiac Safety Evaluations -- Molecular Physiology of Ion Channels That Control Cardiac Repolarization -- Cellular, Molecular, and Pharmacologic Mechanisms Underlying Drug-Induced Cardiac Arrhythmogenesis -- hERG Assay, QT Liability, and Sudden Cardiac Death -- Pharmacogenomics in Drug Development -- Clinical Methodologies and Technical Aspects of Assessing Cardiac Safety of Investigational Drugs: Focus on Cardiac Repolarization -- Assessment of Ventricular Repolarization From Body-Surface ECGs in Humans -- ECG Acquisition and Signal Processing -- Digital 12-Lead Holter vs Standard Resting Supine Electrocardiogram for the Assessment of Drug-Induced QTc Prolongation -- Holter Monitoring for QT -- Application of ELectrocardiology in Clinical Research -- Fundamentals of ECG Interpretation in Clinical Research and Cardiac Safety Assessment -- Design and Conduct of the Thorough Phase I ECG Trial for New Bioactive Drugs -- Use of ECGs in Support of Cardiac Safety in Phase II and III Clinical Trials -- Cardiac Arrhythmia Assessment in Phase IV Clinical Studies -- Statistical Analysis Plans for ECG Data -- Interpretation of Clinical ECG Data -- Regulatory COnsiderations -- The FDA’s Digital ECG Initiative and Its Impact on Clinical Trials -- Quality Control and Quality Assurance for Core ECG Laboratories -- ECG Digital Communities and Electronic Reporting of Cardiac Safety Data.
|
| 650 |
|
0 |
|a Pharmacology.
|
| 650 |
1 |
4 |
|a Pharmacology/Toxicology.
|
| 700 |
1 |
|
|a Morganroth, Joel.
|e editor.
|
| 700 |
1 |
|
|a Gussak, Ihor.
|e editor.
|
| 710 |
2 |
|
|a SpringerLink (Online service)
|
| 773 |
0 |
|
|t Springer eBooks
|